Skip to main content
An official website of the United States government
Español
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Krazati

(krah-ZAH-tee)
A drug used alone or with cetuximab to treat adults with colorectal cancer or non-small cell lung cancer that has spread and has a certain mutation (change) in the KRAS gene. It is used in patients whose cancer was treated with other systemic therapy. It is also being studied in the treatment of other types of cancer. Krazati blocks a protein (KRAS G12C) made by the mutated KRAS gene, which may help keep cancer cells from growing and may kill them. It is a type of targeted therapy. Also called adagrasib.
Search NCI's Dictionary of Cancer Terms